Evidence map›Paper›PMID 33786862›Full record

ArticleHepatology (Baltimore, Md.)2021

The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.

Patrick Starlinger, Joseph C Ahn, Aidan Mullan, Georg P Gyoeri, David Pereyra, Roberto Alva-Ruiz, Hubert Hackl, Thomas Reiberger, Michael Trauner, Jonas Santol and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Serum/Plasma Proteome in Non-Malignant Liver Disease.International journal of molecular sciences · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Patrick StarlingerDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN.ORCID 0000-0002-4666-5337
Joseph C AhnDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Aidan MullanDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Georg P GyoeriDepartment of Surgery, Division of General Surgery, Medical University of Vienna, General Hospital Vienna, Vienna, Austria.ORCID 0000-0002-0863-2876
David PereyraDepartment of Surgery, Division of General Surgery, Medical University of Vienna, General Hospital Vienna, Vienna, Austria.ORCID 0000-0001-6700-9163
Roberto Alva-RuizDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN.
Hubert HacklInstitute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Thomas ReibergerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-4590-3583
Michael TraunerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Jonas SantolDepartment of Surgery, Division of General Surgery, Medical University of Vienna, General Hospital Vienna, Vienna, Austria.
Benedikt SimbrunnerDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Mattias MandorferDivision of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-2330-0017
Gabriela BerlakovichDivision of Transplantation, Department of Surgery, Medical University of Vienna, General Hospital Vienna, Vienna, Austria.
Patrick S KamathDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Julie HeimbachDepartment of Surgery, Division of Transplantation Surgery, Mayo Clinic, Rochester, MN.
Vienna General Hospital · ATMayo Clinic in Arizona · USMedical University of Vienna · ATInnsbruck Medical University · ATMayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsPatients with cirrhosis on the liver transplant (LT) waiting list may die or be removed because of complications of portal hypertension (PH) or infections. von Willebrand factor antigen (vWF-Ag) and C-reactive protein (CRP) are simple, broadly available markers of these processes. APPROACH AND

resultsWe determined whether addition of vWF-Ag and CRP to the Model for End-Stage Liver Disease-Sodium (MELD-Na) score improves risk stratification of patients awaiting LT. CRP and vWF-Ag at LT listing were assessed in two independent cohorts (Medical University of Vienna [exploration cohort] and Mayo Clinic Rochester [validation cohort]). Clinical characteristics, MELD-Na, and mortality on the waiting list were recorded. Prediction of 3-month waiting list mortality was assessed by receiver operating characteristics curve (ROC-AUC). In order to explore potential mechanisms underlying the prognostic utility of vWF-Ag and CRP in this setting, we evaluated their association with PH, bacterial translocation, systemic inflammation, and circulatory dysfunction. In the exploration cohort (n = 269) vWF-Ag and CRP both improved the predictive value of MELD-Na for 3-month waitlist mortality and showed the highest predictive value when combined (AUC: MELD-Na, 0.764; MELD-Na + CRP, 0.790; MELD-Na + vWF, 0.803; MELD-Na + CRP + vWF-Ag, 0.824). Results were confirmed in an independent validation cohort (n = 129; AUC: MELD-Na, 0.677; MELD-Na + CRP + vWF-Ag, 0.882). vWF-Ag was independently associated with PH and inflammatory biomarkers, whereas CRP closely, and MELD independently, correlated with biomarkers of bacterial translocation/inflammation.

conclusionsThe addition of vWF-Ag and CRP-reflecting central pathophysiological mechanisms of PH, bacterial translocation, and inflammation, that are all drivers of mortality on the waiting list for LT-to the MELD-Na score improves prediction of waitlist mortality. Using the vWFAg-CRP-MELD-Na model for prioritizing organ allocation may improve prediction of waitlist mortality and decrease waitlist mortality.

Indexed as

AgedBacterial TranslocationBiomarkersC-Reactive ProteinEnd Stage Liver DiseaseFemaleHumansHypertension, PortalInflammationLiver CirrhosisLiver TransplantationMaleMiddle AgedPrognosisSeverity of Illness IndexSodiumBiomarkersC-Reactive ProteinSodiumvon Willebrand Factor

Identifiers

PMID33786862
PMCPMC8518408
OpenAlexW3143748349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.